MaxCyte, Inc. (NASDAQ:MXCT) Q1 2024 Earnings Call Transcript
ISUN, DTCK and MXCT among mid-day movers
Q1 2024 MaxCyte Inc Earnings Call
MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and ...
MaxCyte Inc (MXCT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue Growth and Strategic Milestones
Q1 2024 MaxCyte Inc Earnings Call Transcript
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.